Tsukubamirai, Japan

Saori Miyano

USPTO Granted Patents = 4 

 

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2022-2025

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Saori Miyano: Innovator in Cancer Therapeutics

Introduction

Saori Miyano is a prominent inventor based in Tsukubamirai, Japan. She has made significant contributions to the field of cancer therapeutics, holding a total of 4 patents. Her work focuses on developing innovative treatments for various types of cancer, showcasing her dedication to improving patient outcomes.

Latest Patents

Miyano's latest patents include a therapeutic agent for breast cancer. This invention discloses a therapeutic agent comprising 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof. Additionally, she has developed a therapeutic agent for bile duct cancer, which also includes the same compound structure as her breast cancer treatment.

Career Highlights

Throughout her career, Saori Miyano has worked with notable organizations such as Eisai R&D Management Co., Ltd. and the National Cancer Center. Her experience in these institutions has allowed her to advance her research and contribute to the development of effective cancer therapies.

Collaborations

Miyano has collaborated with esteemed colleagues, including Atsumi Yamaguchi and Hajime Shimizu. These partnerships have played a crucial role in her research endeavors and have fostered a collaborative environment for innovation.

Conclusion

Saori Miyano is a dedicated inventor whose work in cancer therapeutics has the potential to make a significant impact on patient care. Her innovative patents and collaborations highlight her commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…